Pancreatic Cancer Research

ResearcherThe University of TokyoActive in the last 2 years

Saburo Matsubara

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8182-3524; OpenAlex author ID A5016956041. Sources: OpenAlex.

Their work

Papers
16
Trials
0
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2011: 3 papers · 2012: 2 papers · 2013: 1 paper · 2014: 1 paper · 2015: 2 papers · 2016: 2 papers · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 16

  1. Impact of Statin Use on Survival in Patients With Unresectable Pancreatic cancer Receiving Gemcitabine Plus Nab-Paclitaxel: A Multicenter Retrospective Study. Co-author DOI 10.1097/mpa.0000000000002411↗
  2. A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer. Co-author DOI 10.1007/s10637-018-0691-9↗
  3. A Multicenter Open-Label Randomized Controlled Trial of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001079↗
  4. The Role of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer: A Prospective Cohort Study. Co-author DOI 10.1097/mpa.0000000000000767↗
  5. Thromboembolisms in Advanced Pancreatic Cancer: A Retrospective Analysis of 475 Patients. Co-author DOI 10.1097/mpa.0000000000000889↗
  6. Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites. Co-author DOI 10.1007/s10637-016-0369-0↗
  7. Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer. Co-author DOI 10.1016/j.ejca.2016.05.016↗
  8. Pancreatic cancer with malignant ascites: clinical features and outcomes. Co-author DOI 10.1097/mpa.0000000000000290↗
  9. [IPMN and pancreatic cyst as high risk of pancreatic cancer]. Co-author DOI 10.11405/nisshoshi.112.1474↗
  10. Risk factors for covered metallic stent migration in patients with distal malignant biliary obstruction due to pancreatic cancer. Co-author DOI 10.1111/jgh.12602↗
  11. A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2. Co-author DOI 10.1007/s10637-013-9972-5↗
  12. A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study. Co-author DOI 10.1038/bjc.2012.183↗
  13. Incidental pancreatic cysts found by magnetic resonance imaging and their relationship with pancreatic cancer. Co-author DOI 10.1097/mpa.0b013e31824f5970↗
  14. Comorbidity, not age, is prognostic in patients with advanced pancreatic cancer receiving gemcitabine-based chemotherapy. Co-author DOI 10.1016/j.critrevonc.2010.05.007↗
  15. Duodenal invasion is a risk factor for the early dysfunction of biliary metal stents in unresectable pancreatic cancer. Co-author DOI 10.1016/j.gie.2011.04.046↗
  16. Gemcitabine and oxaliplatin combination chemotherapy for patients with refractory pancreatic cancer. Co-author DOI 10.1159/000328767↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiroyuki Isayama · 16 shared papers, 2011–2025 · strength 0.80
  2. Yousuke Nakai · 16 shared papers, 2011–2025 · strength 0.80
  3. Minoru Tada · 15 shared papers, 2011–2019 · strength 0.60
  4. Hirofumi Kogure · 15 shared papers, 2011–2019 · strength 0.60
  5. Kazuhiko Koike · 14 shared papers, 2011–2019 · strength 0.57
  6. Suguru Mizuno · 12 shared papers, 2011–2019 · strength 0.52
  7. Kei Saito · 7 shared papers, 2015–2025 · strength 0.52
  8. Naminatsu Takahara · 10 shared papers, 2011–2019 · strength 0.47
  9. Tsuyoshi Hamada · 10 shared papers, 2011–2019 · strength 0.45
  10. Tsuyoshi Takeda · 4 shared papers, 2015–2025 · strength 0.36
  11. Takashi Sasaki · 5 shared papers, 2011–2025 · strength 0.35
  12. Dai Mohri · 5 shared papers, 2011–2025 · strength 0.35
  13. Kazunaga Ishigaki · 4 shared papers, 2015–2019 · strength 0.23
  14. Tomotaka Saito · 4 shared papers, 2015–2019 · strength 0.22
  15. Ko Tomishima · 1 shared paper, 2025 · strength 0.20
  16. Hiroki Oyama · 1 shared paper, 2025 · strength 0.20
  17. Makoto Ueno · 1 shared paper, 2025 · strength 0.20
  18. Mitsuhiro Fujishiro · 1 shared paper, 2025 · strength 0.20
  19. Hideaki Ijichi · 4 shared papers, 2013–2019 · strength 0.17
  20. Naoki Sasahira · 7 shared papers, 2011–2015 · strength 0.17
  21. Takashi Sasaki · 6 shared papers, 2011–2015 · strength 0.17
  22. Masao Omata · 5 shared papers, 2011–2012 · strength 0.11
  23. Takahiro Kishikawa · 2 shared papers, 2015–2019 · strength 0.11
  24. Koji Miyabayashi · 3 shared papers, 2013–2015 · strength 0.10
  25. Keisuke Yamamoto · 3 shared papers, 2011–2015 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.